Analysts See $-0.18 EPS for Bavarian Nordic A/S (BVNRY)

March 3, 2018 - By Peter Erickson

 Analysts See $ 0.18 EPS for Bavarian Nordic A/S (BVNRY)

Analysts expect Bavarian Nordic A/S (OTCMKTS:BVNRY) to report $-0.18 EPS on March, 21.They anticipate $0.32 EPS change or 228.57 % from last quarter’s $0.14 EPS. It closed at $13.395 lastly. It is down 0.00% since March 4, 2017 and is . It has underperformed by 16.70% the S&P500.

Bavarian Nordic A/S, a biotechnology company, develops, makes, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company has market cap of $1.26 billion. The firm markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It has a 17.1 P/E ratio. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus.

More notable recent Bavarian Nordic A/S (OTCMKTS:BVNRY) news were published by: which released: “Bavarian Nordic A/S Announces Major Shareholder Notification from Johnson …” on August 22, 2017, also with their article: “Smallpox Pipeline Insight Report 2018 Featuring Bavarian Nordic, Bio Factura …” published on February 26, 2018, published: “Biotech’s Cancer-Vaccine Insanity” on September 15, 2017. More interesting news about Bavarian Nordic A/S (OTCMKTS:BVNRY) were released by: and their article: “Bavarian Nordic Announces Positive Results of Pivotal Phase 3 Study of …” published on February 06, 2018 as well as‘s news article titled: “Bavarian Nordic A/S ADR” with publication date: September 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: